Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Up 5.7% – Should You Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) traded up 5.7% on Friday. The company traded as high as $27.18 and last traded at $27.2250. 109,545 shares traded hands during trading, a decline of 68% from the average session volume of 342,964 shares. The stock had previously closed at $25.76.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research note on Wednesday, July 15th. JPMorgan Chase & Co. started coverage on Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price for the company. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.38.

Kestra Medical Technologies Stock Performance

The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $25.17 and a 200-day moving average of $22.76. The company has a market cap of $1.62 billion, a PE ratio of -10.17 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The business had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.

Insider Buying and Selling at Kestra Medical Technologies

In other news, Director Kevin Reilly sold 2,932 shares of Kestra Medical Technologies stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $25.13, for a total value of $73,681.16. Following the completion of the transaction, the director owned 5,368 shares in the company, valued at $134,897.84. This trade represents a 35.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elizabeth Kwo sold 4,010 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $24.26, for a total transaction of $97,282.60. Following the sale, the director owned 14,116 shares in the company, valued at $342,454.16. The trade was a 22.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 243,598 shares of company stock valued at $5,899,971. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Institutional investors have recently added to or reduced their stakes in the business. Quantinno Capital Management LP bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at about $431,000. California State Teachers Retirement System raised its stake in shares of Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after acquiring an additional 7,844 shares in the last quarter. Spartan Wealth Advisory Services LLC bought a new stake in shares of Kestra Medical Technologies in the 1st quarter worth approximately $603,000. Corient Private Wealth LP boosted its stake in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after purchasing an additional 22,471 shares during the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.